Tag: Phase III Trial
Private Law Firm to Investigate Claims on Behalf of Investors in...
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial
Another delay for the long-awaited therapy.
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
Infants and young children finally get relief from eczema’s terrible itch
DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
Majority of patients achieved histological disease remission in 16 weeks.
DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...
Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Oral Medication Shows Strong Promise for Moderate to Severe Eczema in...
Upadacitinib yielded rapid and significant improvements in patients with moderate to severe atopic dermatitis in phase 3 trials.
FDA Authorizes Moderna Vaccine, Another Pfizer Vaccine Recipient Has Allergic Reaction
PEG compound possible culprit in allergic reactions.
Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and...
Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
Recruitment of Infants Begins for Phase 3 Trial of Cream to...
The trial needs 760 babies aged three weeks or younger whose parents or siblings suffer from either eczema, asthma or food allergies.
